Informações de Nektar Therapeutics

Mais detalhes de Nektar Therapeutics Empresa

Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.



Código da empresaNKTR

Nome da EmpresaNektar Therapeutics

Data de listagemMay 03, 1994

CEOMr. Howard W. Robin

Número de funcionários61

Tipo de títulosOrdinary Share

Fim do ano fiscalMay 03

Endereço455 Mission Bay Boulevard South

CidadeSAN FRANCISCO

Bolsa de valoresNASDAQ Capital Market Consolidated

PaísUnited States of America

Código postal94158

Telefone18554826587

Sitehttps://www.nektar.com/

Código da empresaNKTR

Data de listagemMay 03, 1994

CEOMr. Howard W. Robin

Executivos da empresa Nektar Therapeutics



Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Howard W. Robin

President, Chief Executive Officer, Director

41.83K

-32.35%

Dr. Jonathan Zalevsky, Ph.D.

Senior Vice President, Chief Research and Development Officer

15.15K

-12.71%

Mr. Jeffrey Robert (Jeff) Ajer

Independent Director

2.28K

--

Dr. Diana M. Brainard, M.D.

Independent Director

--

Mr. R. Scott Greer

Independent Director

--

Mr. Robert B. (Rob) Chess

Independent Chairman of the Board

--

Ms. Sandra A. Gardiner

Interim Chief Financial Officer

--

Mr. Mark A. Wilson, J.D.

Senior Vice President, Chief Legal Officer

--

Mr. Corey Davis

Managing Director

--

Mr. Roy A. Whitfield

Lead Independent Director

--

Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Howard W. Robin

President, Chief Executive Officer, Director

41.83K

-32.35%

Dr. Jonathan Zalevsky, Ph.D.

Senior Vice President, Chief Research and Development Officer

15.15K

-12.71%

Mr. Jeffrey Robert (Jeff) Ajer

Independent Director

2.28K

--

Dr. Diana M. Brainard, M.D.

Independent Director

--

Mr. R. Scott Greer

Independent Director

--

Mr. Robert B. (Rob) Chess

Independent Chairman of the Board

--

Detalhamento da receita

Moeda: USDAtualizado em: seg, 6 de out

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

Sem dados

Por RegiãoUSD

Nome

Receita

Proporção

Rest of world

97.05M

98.60%

United States

1.38M

1.40%

Por Empresa

Por Região

Sem dados

Distribuição de ações

Atualizado em: qua, 10 de set

Investidores

Tipos de investidores

Investidores

Proporção

BVF Partners L.P.

6.71%

The Vanguard Group, Inc.

4.99%

Nantahala Capital Management, LLC

3.73%

Millennium Management LLC

3.00%

Emerald Advisers LLC

2.93%

Outro

78.64%

Investidores

Proporção

BVF Partners L.P.

6.71%

The Vanguard Group, Inc.

4.99%

Nantahala Capital Management, LLC

3.73%

Millennium Management LLC

3.00%

Emerald Advisers LLC

2.93%

Outro

78.64%

Tipos de investidores

Investidores

Proporção

Hedge Fund

22.02%

Investment Advisor

17.56%

Investment Advisor/Hedge Fund

9.94%

Research Firm

1.83%

Individual Investor

0.71%

Family Office

0.23%

Venture Capital

0.08%

Pension Fund

0.01%

Outro

47.62%

Participação acionária institucional



Atualizado em: dom, 5 de out

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q3

340

9.78M

51.45%

-2.35M

2025Q2

342

8.92M

53.56%

-2.95M

2025Q1

408

8.48M

68.15%

-4.47M

2024Q4

427

136.20M

73.84%

-69.28M

2024Q3

442

143.71M

78.07%

-57.20M

2024Q2

458

138.43M

75.38%

-54.08M

2024Q1

477

115.32M

62.79%

-91.21M

2023Q4

499

122.94M

64.45%

-94.24M

2023Q3

522

148.15M

77.94%

-68.45M

2023Q2

531

142.56M

75.34%

-88.27M

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

BVF Partners L.P.

1.28M

6.71%

+1.28M

--

Jul 01, 2025

The Vanguard Group, Inc.

729.49K

3.84%

-91.15K

-11.11%

Jun 30, 2025

Nantahala Capital Management, LLC

709.76K

3.73%

+190.49K

+36.68%

Jun 30, 2025

Millennium Management LLC

649.03K

3.41%

+496.45K

+325.35%

Jun 30, 2025

Emerald Advisers LLC

143.29K

0.75%

+389.00

+0.27%

Sep 30, 2025

AQR Capital Management, LLC

427.87K

2.25%

+185.14K

+76.28%

Jun 30, 2025

Acadian Asset Management LLC

420.96K

2.21%

-65.82K

-13.52%

Jun 30, 2025

Balyasny Asset Management LP

386.29K

2.03%

+329.62K

+581.60%

Jun 30, 2025

PRIMECAP Management Company

299.72K

1.58%

-57.25K

-16.04%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

297.81K

1.57%

-576.08K

-65.92%

Jun 30, 2025

Ver Mais

ETFs Relacionados



Atualizado em: dom, 2 de nov

Nome

Proporção

Invesco Dorsey Wright Healthcare Momentum ETF

4.32%

Simplify Health Care ETF

2.66%

SPDR S&P Pharmaceuticals ETF

1.39%

Simplify Propel Opportunities ETF

1.38%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.04%

Invesco NASDAQ Future Gen 200 ETF

0.93%

Invesco Dorsey Wright SmallCap Momentum ETF

0.83%

iShares U.S. Pharmaceuticals ETF

0.4%

Invesco RAFI US 1500 Small-Mid ETF

0.12%

Fidelity Enhanced Small Cap ETF

0.06%

Ver Mais

Invesco Dorsey Wright Healthcare Momentum ETF

Proporção4.32%

Simplify Health Care ETF

Proporção2.66%

SPDR S&P Pharmaceuticals ETF

Proporção1.39%

Simplify Propel Opportunities ETF

Proporção1.38%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

Proporção1.04%

Invesco NASDAQ Future Gen 200 ETF

Proporção0.93%

Invesco Dorsey Wright SmallCap Momentum ETF

Proporção0.83%

iShares U.S. Pharmaceuticals ETF

Proporção0.4%

Invesco RAFI US 1500 Small-Mid ETF

Proporção0.12%

Fidelity Enhanced Small Cap ETF

Proporção0.06%

Dividendo



Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Sem dados

Desdobramento de ações



Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados